The estimated Net Worth of Tony T Kalajian is at least $46.5 Tisíc dollars as of 3 August 2020. Mr. Kalajian owns over 5,000 units of Oncocyte stock worth over $46,500 and over the last 5 years he sold OCX stock worth over $0. In addition, he makes $0 as Senior Vice President a Chief Accounting Officer at Oncocyte.
Tony has made over 2 trades of the Oncocyte stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of OCX stock worth $6,550 on 3 August 2020.
The largest trade he's ever made was buying 10,000 units of Oncocyte stock on 13 September 2019 worth over $19,800. On average, Tony trades about 5,000 units every 108 days since 2019. As of 3 August 2020 he still owns at least 15,000 units of Oncocyte stock.
You can see the complete history of Mr. Kalajian stock trades at the bottom of the page.
Tony T. Kalajian serves as Senior Vice President, Chief Accounting Officer of the Company. Prior to joining Oncocyte, Mr. Kalajian, served as Vice President and Chief Accounting Officer for Oncocyte’s former parent company Lineage Cell Therapeutics, Inc. (formerly known as BioTime, Inc.). While at Lineage from May 2016 to August 2019, Mr. Kalajian concurrently managed and oversaw the financial reporting, compliance and accounting for three other public companies spun off from Lineage, including Oncocyte, Asterias Biotherapeutics, Inc. and AgeX Therapeutics, Inc. Prior to joining Lineage, Mr. Kalajian was the Senior Director of Finance at STAAR Surgical Company, a publicly traded multi-national medical-device developer and manufacturer. Mr. Kalajian is a certified public accountant (CPA) (inactive) with the State of California and brings over 20 years of finance and public accounting experience, including domestic and international financial reporting, initial public offerings, management, business consulting and tax services in various industries including medical devices, ophthalmic, diagnostic, start-ups, ecommerce, alternative energy, manufacturing and retail. Mr. Kalajian held various positions at the public accounting firm of PricewaterhouseCoopers (PwC), where he was a Senior Manager in Audit and Advisory Services. Mr. Kalajian holds a B.S. in accounting, theory and practice from California State University, Northridge and an M.B.A. from the University of Southern California Marshall School of Business.
Tony's mailing address filed with the SEC is 15, Cushing, Irvine Spectrum, Irvine, Orange County, California, 92618, United States.
Over the last 9 years, insiders at Oncocyte have traded over $16,389,842 worth of Oncocyte stock and bought 56,056,405 units worth $102,313,246 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Cell Therapeutics, Inc. Lin... a Partners, L.P.Bradsher Neal.... On average, Oncocyte executives and independent directors trade stock every 37 days with the average trade being worth of $3,382,106. The most recent stock trade was executed by Josh Riggs on 11 April 2024, trading 3,390 units of OCX stock currently worth $10,001.
oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.
Oncocyte executives and other stock owners filed with the SEC include: